Global Pars planitis Treatment Market Size, Trends, and Growth Opportunity, By Treatment (Surgery, Cryotherapy, Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Immunomodulatory Therapy, Others), Diagnosis (X-ray, Magnetic Resonance Imaging (MRI), Blood Tests, Others), Symptoms (Swelling Inside the Eye, Vision Loss, Blurred Vision, Dark Floaters in the Visual Field, Glaucoma, Cataracts, Retinal Detachment, Others), Dosage (Eye Drops, Injection, Tablets, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospital, Clinic, Others), Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) By Region and forecast till 2030.
Global Pars planitis Treatment Market
Global Pars planitis Treatment Market was valued at USD 596.15 Billion in 2022 and is slated to reach USD 1000.12 Billion by 2030 at a CAGR of 6.68 % from 2023-2030.
The center layer, or uvea, of the eye, can become inflamed, causing pars planitis. The choroid and the iris, the colored portion of the eye, are separated by a narrow space called the pars plana, which swells in this condition. Over time, this may result in vision loss, black, blurry, or floating portions of vision. The problem could worsen and lead to cataracts, macular edema, and retinal detachment.
Market Drivers
The market expands during the forecast period due to the rising prevalence of pars planitis. The majority of children's intermediate uveitis cases are asymptomatic. In France and the United States (U.S.), there are 1.4 to 2 instances per 100,000 people per year, according to reports. Additionally, pars planitis was found to be the leading cause of pediatric uveitis in a retrospective investigation by Ozdal et al., with a rate of 24%. Thus, there is a greater need for pars planitis treatment methods as a result of its rising incidence. The market expands as a result of this factor. The number of pars planitis treatments is expanding, which boosts the market. Cryotherapy or laser photocoagulation, pars plana vitrectomy, periocular corticosteroid (CS) injections, followed by oral prednisone if those are found insufficient, and immunosuppressive drugs are among the available treatments. Periocular CS injections are beneficial, especially for patients with macular edema and unilateral or asymmetrical involvement. This contributes to the market's expansion.
Market Restraints
The expensive cost of various treatment methods further inhibits market expansion. Cryotherapy, laser photocoagulation, and pars plana vitrectomy are all very expensive forms of treatment. Most hospitals in undeveloped and underdeveloped nations cannot afford them, which starts to have an impact on the patients' health. This constraint prevents market growth.
Impact of COVID-19
The COVID-19 epidemic, which is mostly blamed on the lockdown being implemented by major countries, is anticipated to have an impact on the market for treating uveitis. The market under study was directly impacted by the supply chain disruption because numerous drugs were unable to reach the market promptly. Patients with uveitis may be more likely to contract infections like COVID-19. Throughout the forecast period, the aforementioned factors are anticipated to adversely affect the revenue trajectory of the worldwide uveitis treatment market. The global market for uveitis treatment is anticipated to rebound, though, as the relevant regulating agencies have abolished these imposed lockdowns.
Recent Developments
The FDA authorized XIPERE (triamcinolone acetonide), according to a statement released by Bausch + Lomb and Clearside Biomedical in October 2021. Injectable suspension XIPERE is given via a suprachoroidal channel to treat macular edema brought on by uveitis.
In December 2020, Alimera Sciences Europe Limited launched ILUVIEN in the Netherlands. ILUVIEN is used to treat diabetic macular edoema (DME) and non-infectious uveitis affecting the posterior region (NIPU). The launch strategy involves expanding geographically to make ILUVIEN available to more physicians and patients in more markets.
Market Segmentation
Global Pars planitis Treatment Market is segmented By Treatment, Symptoms, Diagnosis, Route of Administration, Dosage, End-Users, and Distribution Channel. By Treatment such as Surgery, Cryotherapy, Corticosteroids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Immunomodulatory Therapy, and Others. By Diagnoses such as X-rays, Magnetic Resonance Imaging (MRI), Blood Tests, and Others. By Symptoms such as Swelling Inside the Eye, Vision Loss, Blurred Vision, Dark Floaters in the Visual Field, Glaucoma, Cataracts, Retinal Detachment, and Others. By Dosages such as Eye Drops, Injections, Tablets, and Others. By Route of Administration such as Intravenous, Oral, and Others. By End-Users such as hospitals, clinics, Others. By Distribution Channels such as Retail Pharmacies, Hospital Pharmacy, and Online Pharmacy.
Regional Analysis
Global Pars planitis Treatment Market is segmented into five regions Americas, Europe, Asia-Pacific, and the Middle East & Africa. Due to the expanding patient base and increasing investment in the healthcare industry, Asia-Pacific is anticipated to expand throughout the projection for the pars planitis treatment market. Additionally, the industry expands as a result of rising government backing for its diagnostic and treatments. Because of its large number of key market players and high level of disposable income, North America will continue to dominate the market over the forecast period. The region's well-developed healthcare infrastructure will also boost market expansion.
Key Players
This report includes a list of numerous Key Players, namely Aurobindo Pharma (India), Teva Pharmaceutical Industries Ltd.(Israel), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Cortex Technology (Denmark), Bayer AG (Germany), Zimmer Medizin Systeme GmbH (Germany), Medtronic (Ireland), Sun Pharmaceutical Industries Ltd. (India), Quantum Cryogenics (U.K.).
Market Taxonomy
By Treatment
• Corticosteroid
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Surgery
• Cryotherapy
• Immunomodulatory Therapy
• Others
By Diagnosis
• Blood Tests
• X-ray
• Magnetic Resonance Imaging (MRI)
• Others
By Symptoms
• Blurred Vision
• Dark Floaters in the Visual Field
• Swelling Inside the Eye
• Vision Loss
• Glaucoma, Cataracts
• Retinal Detachment
• Others
By Dosage
• Injection
• Tablets
• Eye Drops
• Others
By Route of Administration
• Oral
• Intravenous
• Others
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
By End User
• Clinic
• Hospital
• Others
By Region
• North America Latin America
• Europe
• Asia Pacific
• Middle East & Africa.
Global Pars planitis Treatment Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Pars planitis Treatment Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Pars planitis Treatment Market, By Treatment
5.1 Y-o-Y Growth Comparison, By Treatment
5.2 Global Pars planitis Treatment Market Share Analysis, By Treatment
5.3 Global Pars planitis Treatment Market Size and Forecast, By Treatment
5.3.1 Corticosteroid
5.3.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.3.3 Surgery
5.3.4 Cryotherapy
5.3.5 Immunomodulatory Therapy
5.3.6 Others
6 Global Pars planitis Treatment Market, By Diagnosis
6.1 Y-o-Y Growth Comparison, By Diagnosis
6.2 Global Pars planitis Treatment Market Share Analysis, By Diagnosis
6.3 Global Pars planitis Treatment Market Size and Forecast, By Diagnosis
6.3.1 Blood Tests
6.3.2 X-ray
6.3.3 Magnetic Resonance Imaging (MRI)
6.3.4 Others
7 Global Pars planitis Treatment Market, By Symptoms
7.1 Y-o-Y Growth Comparison, By Symptoms
7.2 Global Pars planitis Treatment Market Share Analysis, By Symptoms
7.3 Global Pars planitis Treatment Market Size and Forecast, By Symptoms
7.3.1 Blurred Vision
7.3.2 Dark Floaters in the Visual Field
7.3.3 Swelling Inside the Eye
7.3.4 Vision Loss
7.3.5 Glaucoma, Cataracts
7.3.6 Retinal Detachment
7.3.8 Others
8 Global Pars planitis Treatment Market, By Dosage
8.1 Y-O-Y Growth Comparison, By Dosage
8.2 Global Pars planitis Treatment Market Share Analysis, By Dosage
8.3 Global Pars planitis Treatment Market Size and Forecast, By Dosage
8.3.1 Injection
8.3.2 Tablets
8.3.3 Eye Drops
8.3.4 Others
9 Global Pars planitis Treatment Market, By Route of Administration
9.1 Y-O-Y Growth Comparison, By Route of Administration
9.2 Global Pars planitis Treatment Market Share Analysis, By Route of Administration
9.3 Global Pars planitis Treatment Market Size and Forecast, By Route of Administration
9.3.1 Oral
9.3.2 Intravenous
9.3.3 Others
10 Global Pars planitis Treatment Market, By Distribution channel
10.1 Y-O-Y Growth Comparison, By Distribution channel
10.2 Global Pars planitis Treatment Market Share Analysis, By Distribution channel
10.3 Global Pars planitis Treatment Market Size and Forecast, By Distribution channel
10.3.1 Hospital Pharmacy
10.3.2 Retail Pharmacy
10.3.3 Online Pharmacy
11 Global Pars planitis Treatment Market, By End-Use
11.1 Y-O-Y Growth Comparison, By End-Use
11.2 Global Pars planitis Treatment Market Share Analysis, By End-Use
11.3 Global Pars planitis Treatment Market Size and Forecast, By End-Use
11.3.1 Clinic
11.3.2 Hospital
11.3.3 Others
12 Global Pars planitis Treatment Market, By Region
12.1 Global Pars planitis Treatment Market Share Analysis, By Region
12.2 Global Pars planitis Treatment Market Share Analysis, By Region
12.3 Global Pars planitis Treatment Market Size and Forecast, By Region
13 North America Pars planitis Treatment Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 North America Pars planitis Treatment Market Share Analysis, By Treatment
13.3 North America Pars planitis Treatment Market Size and Forecast, By Diagnosis
13.4 North America Pars planitis Treatment Market Size and Forecast, By Symptoms
13.5 North America Pars planitis Treatment Market Size and Forecast, By Dosage
13.6 North America Pars planitis Treatment Market Size and Forecast, By Route of Administration
13.7 North America Pars planitis Treatment Market Size and Forecast, By Distribution channel
13.8North America Pars planitis Treatment Market Size and Forecast, By End-Use
13.9 North America Pars planitis Treatment Market Size and Forecast, By Country
13.9.1 U.S.
13.9.2 Canada
13.9.3 Mexico
14 EuropePars planitis Treatment Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Europe Pars planitis Treatment Market Share Analysis, By Treatment
14.3 Europe Pars planitis Treatment Market Size and Forecast, By Diagnosis
14.4 Europe Pars planitis Treatment Market Size and Forecast, By Symptoms
14.5 Europe Pars planitis Treatment Market Size and Forecast, By Dosage
14.6 Europe Pars planitis Treatment Market Size and Forecast, By Route of Administration
14.7 Europe Pars planitis Treatment Market Size and Forecast, By Distribution channel
14.8 Europe Pars planitis Treatment Market Size and Forecast, By End-Use
14.9 Europe Pars planitis Treatment Market Size and Forecast, By Country
14.9.1 Germany
14.9.2 France
14.9.3 UK
14.9.4. Rest of Europe
15 Asia Pacific Pars planitis Treatment Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Asia Pacific Pars planitis Treatment Market Share Analysis, By Treatment
15.3 Asia Pacific Pars planitis Treatment Market Size and Forecast, By Diagnosis
15.4 Asia Pacific Pars planitis Treatment Market Size and Forecast, By Symptoms
15.5 Asia Pacific Pars planitis Treatment Market Size and Forecast, By Dosage
15.6 Asia Pacific Pars planitis Treatment Market Size and Forecast, By Route of Administration
15.7 Asia Pacific Pars planitis Treatment Market Size and Forecast, By Distribution channel
15.8 Asia Pacific Pars planitis Treatment Market Size and Forecast, By End-Use
15.9 Asia Pacific Pars planitis Treatment Market Size and Forecast, By Country
15.9.1 China
15.9.2 Japan
15.9.3 India
15.9.4. Rest of Asia Pacific
16 Latin America Pars planitis Treatment Market Analysis and Forecast (2023-2030)
16.1 Introduction
16.2 Latin America Pars planitis Treatment Market Share Analysis, By Treatment
16.3 Latin America Pars planitis Treatment Market Size and Forecast, By Diagnosis
16.4 Latin America Pars planitis Treatment Market Size and Forecast, By Symptoms
16.5 Latin America Pars planitis Treatment Market Size and Forecast, By Dosage
16.6 Latin America Pars planitis Treatment Market Size and Forecast, By Route of Administration
16.7 Latin America Pars planitis Treatment Market Size and Forecast, By Distribution channel
16.8 Latin America Pars planitis Treatment Market Size and Forecast, By End-Use
16.9 Latin America Pars planitis Treatment Market Size and Forecast, By Country
16.9.1. Brazil
16.9.2.Rest of Latin America
17 Middle East Pars planitis Treatment Market Analysis and Forecast (2023-2030)
17.1 Introduction
17.2 Middle East Pars planitis Treatment Market Share Analysis, By Treatment
17.3 Middle East Pars planitis Treatment Market Size and Forecast, By Diagnosis
17.4 Middle East Pars planitis Treatment Market Size and Forecast, By Symptoms
17.5 Middle East Pars planitis Treatment Market Size and Forecast, By Dosage
17.6 Middle East Pars planitis Treatment Market Size and Forecast, By Route of Administration
17.7 Middle East Pars planitis Treatment Market Size and Forecast, By Distribution channel
17.8 Middle East Pars planitis Treatment Market Size and Forecast, By End-Use
17.9 Middle East Pars planitis Treatment Market Size and Forecast, By Country
17.9.1. Saudi Arabia
17.9.2. UAE
17.9.3. Egypt
17.9.4. Kuwait
17.9.5. South Africa
18 Competitive Analysis
18.1 Competition Dashboard
18.2 Market share Analysis of Top Vendors
18.3 Key Development Strategies
19Company Profiles
19.1 Aurobindo Pharma (India)
19.1.1 Overview
19.1.2 Offerings
19.1.3 Key Financials
19.1.4 Business Segment & Geographic Overview
19.1.5 Key Market Developments
19.1.6 Key Strategies
19.2 Teva Pharmaceutical Industries Ltd.(Israel)
19.2.1 Overview
19.2.2 Offerings
19.2.3 Key Financials
19.2.4 Business Segment & Geographic Overview
19.2.5 Key Market Developments
19.2.6 Key Strategies
19.3 AbbVie Inc. (U.S.)
19.3.1 Overview
19.3.2 Offerings
19.3.3 Key Financials
19.3.4 Business Segment & Geographic Overview
19.3.5 Key Market Developments
19.3.6 Key Strategies
19.4 Novartis AG (Switzerland)
19.4.1 Overview
19.4.2 Offerings
19.4.3 Key Financials
19.4.4 Business Segment & Geographic Overview
19.5 Key Market Developments
19.4.6 Key Strategies
19.5 Cortex Technology (Denmark)
19.5.1 Overview
19.5.2 Offerings
19.5.3 Key Financials
19.5.4 Business Segment & Geographic Overview
19.5.5 Key Market Developments
19.5.6 Key Strategies
19.6 Bayer AG (Germany)
19.6.1 Overview
19.6.2 Offerings
19.6.3 Key Financials
19.6.4 Business Segment & Geographic Overview
19.6.5 Key Market Developments
19.6.6 Key Strategies
19.7 Zimmer Medizin Systeme GmbH (Germany)
19.7.1 Overview
19.7.2 Offerings
19.7.3 Key Financials
19.7.4 Business Segment & Geographic Overview
19.7.5 Key Market Developments
19.7.6 Key Strategies
19.8 Medtronic (Ireland)
19.8.1 Overview
19.8.2 Offerings
19.8.3 Key Financials
19.8.4 Business Segment & Geographic Overview
19.8.5 Key Market Developments
19.8.6 Key Strategies
19.9 Sun Pharmaceutical Industries Ltd. (India)
19.9.1 Overview
19.9.2 Offerings
19.9.3 Key Financials
19.9.4 Business Segment & Geographic Overview
19.9.5 Key Market Developments
19.9.6 Key Strategies
19.10 Quantum Cryogenics (U.K.)
19.10.1 Overview
19.10.2 Offerings
19.10.3 Key Financials
19.10.4 Business Segment & Geographic Overview
19.10.5 Key Market Developments
19.10.6 Key Strategies
